Quince Therapeutics Updates Pipeline Progress, Eyes Enrollment for Pivotal Phase 3 Trial in Ataxia-Telangiectasia, Reported Q1 EPS Loss of $(0.26), Cash Balance of $67.8M
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today